Judy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.
Dr. Judy Garber, Chief of the Division for Cancer Genetics and Prevention at Dana-Farber Cancer
Advertisement
Articles by Dr. Judy Garber, Chief of the Division for Cancer Genetics and Prevention at Dana-Farber Cancer
Advertisement
Latest Updated Articles
A Conversation about Somatic, Incidental Germline, and Standalone Germline Testing in Clinical PracticePublished: June 7th 2021 | Updated:
Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast CancerPublished: June 22nd 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
5